Literature DB >> 30947111

Optimizing dosing of nitrofurantoin from a PK/PD point of view: What do we need to know?

Rixt A Wijma1, Fiona Fransen2, Anouk E Muller3, Johan W Mouton4.   

Abstract

Nitrofurantoin is an old antibiotic and an important first-line oral antibiotic for the treatment of uncomplicated urinary tract infections. However despite its long term use for over 60 years, little information is available with respect to its dose justification and this may be the reason of highly variable recommended doses and dosing schedules. Furthermore, nitrofurantoin is not a uniform product -crystal sizes of nitrofurantoin, and therefore pharmacokinetic properties, differ significantly by product. Moreover, pharmacokinetic profiling of some products is even lacking, or difficult to interpret because of its unstable chemical properties. Pharmacokinetic and pharmacodynamic data is now slowly becoming available. This review provides an overview of nitrofurantoins antibacterial, pharmacokinetic and pharmacodynamic properties. This shows that a clear rationale of current dosing regimens is scanty.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibiotic resistance; Pharmacodynamics; Pharmacokinetics; Urinary tract infections

Mesh:

Substances:

Year:  2019        PMID: 30947111     DOI: 10.1016/j.drup.2019.03.001

Source DB:  PubMed          Journal:  Drug Resist Updat        ISSN: 1368-7646            Impact factor:   18.500


  4 in total

1.  Oral Fosfomycin Treatment for Enterococcal Urinary Tract Infections in a Dynamic In Vitro Model.

Authors:  Iain J Abbott; Elke van Gorp; Aart van der Meijden; Rixt A Wijma; Joseph Meletiadis; Jason A Roberts; Johan W Mouton; Anton Y Peleg
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

Review 2.  Nitrofurantoin and glucose-6-phosphate dehydrogenase deficiency: a safety review.

Authors:  Judith Recht; Vilada Chansamouth; Nicholas J White; Elizabeth A Ashley
Journal:  JAC Antimicrob Resist       Date:  2022-05-03

3.  Therapeutic Efficacy of Orally Administered Nitrofurantoin against Animal African Trypanosomosis Caused by Trypanosoma congolense Infection.

Authors:  Keisuke Suganuma; David D N'Da; Ken-Ichi Watanabe; Yusuke Tanaka; Ehab Mossaad; Afraa Elata; Noboru Inoue; Shin-Ichiro Kawazu
Journal:  Pathogens       Date:  2022-03-09

4.  Stimulation of de novo glutathione synthesis by nitrofurantoin for enhanced resilience of hepatocytes.

Authors:  Bob van de Water; Marcel Leist; Stefan Schildknecht; Lukas S Wijaya; Carina Rau; Theresa S Braun; Serif Marangoz; Vincent Spegg; Matthijs Vlasveld; Wiebke Albrecht; Tim Brecklinghaus; Hennicke Kamp; Joost B Beltman; Jan G Hengstler
Journal:  Cell Biol Toxicol       Date:  2021-05-22       Impact factor: 6.819

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.